Risperidone in Cocaine-Dependent Patients with Comorbid Psychiatric Disorders
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: : A high percentage of individuals with cocaine dependence have a comorbid psychiatric illness, which complicates treatment of the substance abuse. This report will describe clinical experience using risperidone in cocaine-dependent patients with psychiatric disorders. METHOD: : Sixteen male patients with cocaine dependence and comorbid psychiatric disorder (DSM-III-R) diagnoses, who were admitted to a voluntary, post-detoxification, intermediate-care inpatient substance abuse program, were started on risperidone (mean starting dose 2.3 mg/day) in an open-label, naturalistic trial. Patients were assessed weekly using the Clinical Global Impressions scale to assess overall functioning, a Likert scale for craving, the Abnormal Involuntary Movement Scale, interviews with substance abuse counselors and patients, and laboratory tests. All patients had at least one other substance use diagnosis besides cocaine dependence, and 13 patients were taking another psychiatric medication. RESULTS: : Of the 16 patients, 13 (81%) were rated improved or much improved on the CGI scale, and all patients reported mild or no craving at the last assessment (after a mean of 32.6 days of risperidone treatment). No patient developed extrapyramidal symptoms or hypomania. Compared to a 32% historical completion rate for patients receiving treatment as usual, fourteen (88%) of these patients completed the program, and 9 moved on to the next level of care. CONCLUSION: : The results of this naturalistic trial suggest that risperidone is safe and well tolerated in patients with cocaine dependence and comorbid psychiatric illness. In the short term, risperidone may also be effective in reducing cocaine craving and use and may increase the likelihood of completing substance abuse treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Risperidone has been studied alone and as an add‐on agent for cocaine and for methamphetamine use disorders with level 3 evidence for efficacy.711, 712”
Citations
Cites
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500150065028 · Cited by 869
Crits-Christoph, P. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.493 · Cited by 496
Quetiapine in bipolar disorder and cocaine dependence
Brown, E. S., Nejtek, V. A., Perantie, D. C., & Bobadilla, L. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.02229.x · Cited by 122
Risperidone for the Treatment of Cocaine Dependence: Randomized, Double-Blind Trial
Grabowski, J., Rhoades, H., Silverman, P., Schmitz, J. M., Stotts, A., Creson, D., & Bailey, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00003 · Cited by 116
Validity of Substance Use Self-Reports in Dually Diagnosed Outpatients
Weiss, R. D., Najavits, L. M., Greenfield, S. F., Soto, J. A., Shaw, S. R., & Wyner, D. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.127 · Cited by 115
Retention of Cocaine Abusers in Outpatient Psychotherapy
Kleinman, P. H., Kang, S.-Y., Lipton, D. S., Woody, G. E., Kemp, J., & Millman, R. B. (1992) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999209001609 · Cited by 106
Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence
LeDuc, P. A., & Mittleman, G. (1995) · Psychopharmacology · doi:10.1007/bf02246489 · Cited by 104
Risperidone Decreases Craving and Relapses in Individuals with Schizophrenia and Cocaine Dependence
Smelson, D. A., Losonczy, M. F., Davis, C. W., Kaune, M., Williams, J., & Ziedonis, D. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700710 · Cited by 99
Gabapentin in the Treatment of Cocaine Dependence: A Case Series
Myrick, H., Henderson, S., Brady, K. T., & Malcolm, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0105 · Cited by 95
Research works printed but not linked: 2
- Albanese, 1994, Am J Psychiatry, 151, 780
- Conley, 1997, Schizophr Res, 24, 190
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Beaulieu, S., Saury, S., Sareen, J., Tremblay, J., Schütz, C. G., McIntyre, R. S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400105 · Cited by 38
Metadata
- Authors
- ALBANESE, M. J., & SUH, J. J.
- Affiliations
- Cambridge Health Alliance (US)
- Venue
- Journal of Psychiatric Practice
- Published
- 2006-09
- Volume
- 12
- Issue
- 5
- Pages
- 306-311
- ISSN
- 1527-4160 (ISSN-L)
- 1538-1145
- OpenAlex
- W2079646955
- Cited by
- 20
- References
- 26
- Citations by year
- 2025: 1 · 2021: 1 · 2018: 2 · 2017: 2 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychiatric Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- risperidone, cocaine dependence, psychiatric comorbidity, cocaine craving, addiction treatment, treatment completion, extrapyramidal symptoms, hypomania
- MeSH terms
- Adolescent, Adult, Mental Disorders, Counseling, Health Status, Humans, Disruptive, Impulse Control, and Conduct Disorders, Intermediate Care Facilities, Male, Inactivation, Metabolic, Middle Aged, Surveys and Questionnaires, Severity of Illness Index, Time Factors, Antipsychotic Agents, Comorbidity, Diagnosis, Dual (Psychiatry), Risperidone, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone in Cocaine-Dependent Patients with Comorbid Psychiatric Disorders. https://app.cochat.ai/papers/10.1097/00131746-200609000-00005
- The paper
- ALBANESE, M. J., & SUH, J. J. (2006). Risperidone in Cocaine-Dependent Patients with Comorbid Psychiatric Disorders. Journal of Psychiatric Practice. https://doi.org/10.1097/00131746-200609000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.